Search results for "prova."
showing 10 items of 148 documents
Immediatezza, incidente probatorio, usura probatoria, art. 238 bis c.p.p.
2015
Lo studio ha per oggetto l'assetto della prova penale nei processi di criminalità organizzata alla luce delle numerose deroghe ai principi di acquisizione della prova. In particolare viene focalizzata l'attenzione sulle deroghe al principio di immediatezza con l'estensione dei casi di incidente probatorio e della c.d. circolazione probatoria, sebbene con i temperamenti susseguenti alla legge attuativa sul giusto processo. L'approccio è di tipo critico in quanto la fisionomia disegnata in origine e poi modificata rimane ancora oggi sfigurata rispetto alle linee tracciate dal 'codice Vassalli'.
“La trattativa che non c’è”. La corte di appello di Palermo conferma l’assoluzione per l’ex ministro Mannino
2020
Il noto processo, denominato Trattativa Stato-Mafia, si è posto all’attenzione dei giuristi e degli storici per la peculiare configurazione delle condotte criminose in contestazione involgendo, oltre che il ritenuto carattere illecito della “Trattativa” e l’individuazione degli elementi costitutivi del reato, lo stesso orizzonte cronologico degli eventi e la loro ricostruzione. L’esistenza di patti compromissori tra “Cosa nostra” e lo Stato italiano aventi come protagonisti i vertici delle istituzioni, basati su di una reciprocità di scambi tali da condizionare negativamente il sistema democratico, si è rivelato tema di accertamento sfuggente e incerto. Il contributo mette in evidenza le fr…
Sbarchi
2021
During 2020, the Mediterranean Sea was again the testing ground for migration flows from North Africa and the Middle East to Italy, Greece and Spain. 2020 was also a complex year due to the spread of the COVID-19 pandemic. Movements between countries were affected by the spread of the virus that spared no one and imposed the need to reflect on 'global health' and the consequences that this has, also in the relationship between countries and in travel.
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
2014
Abstract: In the past decade, the advent of targeted therapy led to a silent revolution in the war against lung cancer and a significant evolution on the concept of Phase I clinical trials design. Thanks to the specificity of their target, the new drugs have radically changed NSCLC treatment, leading to the development of personalized strategies. The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development, characterized by modern, biomarker-driven, early clinical trial design and shorte…
La prova retorica tra esperienza romanistica e moderno processo penale
1998
Prova per testimoni del pagamento e della remissione
2010
Prova testimoniale e patti posteriori alla formazione del documento
2010
Risk analysis in bioequivalence and biowaiver decisions
2013
This article evaluates the current biowaiver guidance documents published by the FDA, EU and WHO from a risk based perspective. The authors introduce the use of a Failure Mode and Effect Analysis (FMEA) risk calculation tool to show that current regulatory documents implicitly limit the risk for bioinequivalence after granting a biowaiver by reduction of the incidence, improving the detection and limiting the severity of any unforeseen bioinequivalent product. In addition, the authors use the risk calculation to expose yet unexplored options for future extension of comparative in vitro tools for biowaivers.
Regulatory evaluation of Glybera in Europe — two committees, one mission
2013
Representing the first gene therapy to be approved in the Western world, alipogene tiparvovec (Glybera; Uniqure) has recently been said to have had a “substantial impact from a regulatory perspective” (Nature Rev. Drug Discov. 11, 664; 2012) 1 . The therapy was granted marketing authorization in the European Union for the treatment of lipoprotein lipase deficiency, which results in a clinically heterogeneous condition with a risk of potentially life-threatening pancreatitis 2 , at the end of 2012. The decision followed a positive opinion by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) 3